Across TCGA pan-cancer cohorts, FNTB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FNTB data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher FNTB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FNTB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
BRCA, LIHC, and UCEC are the cancer types where FNTB Mutation most reproducibly stratifies survival.